Can study data spur Merck CV sales?
Merck said in November that a long-running clinical trial finally demonstrated the impact of its Zetia cholesterol-lowering treatment on cardiovascular outcomes. The results from the so-called IMPROVE-IT trial are expected to shore up Zetia/Vytorin sales, analysts said, after the first trial showing that a non-statin added to a statin reduces cardiovascular events. Doctors now may…